Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

@article{Ward2020Phase1T,
  title={Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants},
  author={Brian J. Ward and Philipe A M Gobeil and Annie S{\'e}guin and J. Atkins and Iohann Boulay and P Charbonneau and Manon Couture and Marc‐Andr{\'e} D'Aoust and J. Dhaliwall and Carolyn Finkle and Karl Hager and Asif Mahmood and Alexander I Makarkov and M. Cheng and Stéphane Pillet and P A Schimke and Sylvie St-Martin and Sonia Trépanier and Nathalie Landry},
  journal={medRxiv},
  year={2020}
}
Background: The stabilized prefusion form of the SARS-CoV-2 spike protein is produced by transient expression in Nicotiana benthamiana. The trimeric spike glycoproteins are displayed at the surface of self-assembling Virus-Like-Particles that mimic the shape and the size of the virus. The candidate vaccine (CoVLP) administered alone or with AS03 or CpG1018 adjuvants was evaluated in a Phase 1 trial in healthy adults. (ClinicalTrials.gov number NCT04450004) Methods: The study was a randomized… Expand
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
TLDR
Interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations are presented. Expand
Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates
TLDR
This is the first report demonstrating the immunogenicity of plant-produced SARS-CoV-2 RBD protein in mice and non-human primates and demonstrated that the plant- produced RBD has the potential to be used as an effective vaccine candidate against Sars-Cov-2. Expand
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
TLDR
The different types of COVID-19 candidate vaccines that are currently being evaluated in preclinical and clinical trial phases are reviewed along with advantages, disadvantages or adverse reactions, if any. Expand
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
TLDR
The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease and there more than 64 vaccine candidates, most of them aiming to induce neutralizing antibodies against the spike protein (S). Expand
Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19
  • Kun Xu, Yaling An, +20 authors Lianpan Dai
  • Medicine
  • Emerging microbes & infections
  • 2021
TLDR
Results support AdC7-RBD-tr2 as a promising COVID-19 vaccine candidate after it was found vaccination via either intramuscular or intranasal route was highly immunogenic in mice to elicit both humoral and cellular immune responses. Expand
Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review
Coronavirus Infectious Disease (COVID-19) has taken heavy toll on human lives and world economy across the globe. Till date, there is no specific treatment and pathological effects in COVID-19 areExpand
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
TLDR
The different types of vaccines designed and developed against SARS-CoV-2 are reviewed, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S Glycoprotein. Expand
Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
TLDR
It is stressed that thermostabilizing technologies are available to enable cold chain-free vaccine storage and distribution, as well as potential needle-free vaccination. Expand
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
TLDR
Comparing how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented, is compared. Expand
A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics
TLDR
This review will look at the plant biotechnology platform that can provide the best fight against this global pandemic. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 53 REFERENCES
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults
TLDR
Overall, the 30 μg dose produced the most consistent humoral and cellular responses in both 18–49 and ≥50 years old subjects, strongly supporting the clinical development of this candidate vaccine. Expand
A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.
TLDR
Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines and induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells. Expand
Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial
TLDR
The ability of the low dose GLA-SE-adjuvanted H5VLP to elicit both humoral response and a sustained cross-reactive CMI in healthy adults is very attractive and could result in significant dose-sparing in a pandemic situation. Expand
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
TLDR
The first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study, induced significant immune responses in the majority of recipients after a single immunisation. Expand
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
TLDR
Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS. Expand
Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages
TLDR
Data suggest that HA delivery to antigen-presenting cells on plant-derived VLPs facilitates antigen uptake, endosomal processing, and cross-presentation, which may help to explain the broad andCross-reactive immune responses generated by these vaccines. Expand
Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.
TLDR
Results show that plant-made HA VLP vaccines elicit both strong antibody responses and poly-functional, cross-reactive memory T cells that persist for at least 6 months after vaccination. Expand
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
TLDR
AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. Expand
Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines.
TLDR
VLP vaccines bearing influenza HA glycoproteins can elicit transient IgG and, in some cases, IgE responses that are not associated with either the development or worsening of allergic/hypersensitivity symptoms. Expand
Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
TLDR
Two phase 3 efficacy studies of a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine manufactured in plants in adults aged 18-64 years and 65-plus, showing relative vaccine efficacy to prevent laboratory-confirmed influenza-like illness caused by any influenza strain are described. Expand
...
1
2
3
4
5
...